A commercial prebiotic made from three mushroom extracts improved symptoms in 80% of Crohn’s patients, compared to just 16.7% on placebo. The supplement, Mycodigest, also increased gut levels of short-chain fatty acid–producing bacteria like Parabacteroides distasonis and Faecalimonas umbilicata, while inflammatory markers remained unchanged. The study was partially funded by Mycolivia, the Israeli company behind the product. While the mushrooms aren’t named in the paper, Mycodigest is listed elsewhere as containing turkey tail (Trametes versicolor), lion’s mane (Hericium erinaceus), and sun mushroom (Agaricus blazei Murill). While the supplement is listed on Hebrew-language health sites, international access seems limited.